Jan Geissler's guest appearances

Jan Geissler

EHA Hematology Podcast

17th European Haematology Association (EHA) Congress

2012 Oncopolicy Forum

John Porter

Michael Keating

Willem Fibbe

Martine Piccart

Charles Mullighan

Jing Chen

Mark Frattini

Giora Sharf

OwlTail

Whilst personalised medicine offers many benefits, these treatment options are typically very expensive and unlikely to be universally available. Ian Banks and Jan Geissler talk to ecancer.tv about the difficulties associated with such discrepancies in treatment availability and outline the contribution cancer patient groups can make informing patients about personalised therapies, and helping clinicians understand what patients want from new treatments.

Whilst personalised medicine offers many benefits, these treatment options are typically very expensive and unlikely to be universally available. Ian Banks and Jan Geissler talk to <a href="http://ecancer.tv" rel="nofollow" target="_blank">ecancer.tv</a> about the difficulties associated with such discrepancies in treatment availability and outline the contribution cancer patient groups can make informing patients about personalised therapies, and helping clinicians understand what patients want from new treatments.

The role of patients in personalised medicine development: Ian Banks; Jan Geissler

Leading patient advocate Jan Gessler talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about patient advocacy in haematologic malignancy treatment. Quality of life treatment for patients does not just include day-to-day caring, but the effects on the patient community as a whole.  A session at EHA 17 showed doctor's and patient's common miscommunications which occur when doctors misinterpret how patients feel either because of due to misunderstandings or lack of information. Recently, guidelines on the quality of life care was published for haematologists, setting criteria and providing an example of how doctors should address and assess these issues.

Leading patient advocate Jan Gessler talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about patient advocacy in haematologic malignancy treatment. Quality of life treatment for patients does not just include day-to-day caring, but the effects on the patient community as a whole. A session at EHA 17 showed doctor's and patient's common miscommunications which occur when doctors misinterpret how patients feel either because of due to misunderstandings or lack of information. Recently, guidelines on the quality of life care was published for haematologists, setting criteria and providing an example of how doctors should address and assess these issues.

Patient and doctor communication and quality of life guidelines: Jan Geissler – CML Advocates Network